Ulrike Stentzel1, Neeltje van den Berg2, Lara N Schulze3, Thea Schwaneberg2,4, Franziska Radicke2, Jens M Langosch5, Harald J Freyberger3,6, Wolfgang Hoffmann2, Hans-Jörgen Grabe3. 1. Institute for Community Medicine, University Medicine Greifswald, Ellernholzstraße 1-2, 17487, Greifswald, Germany. ulrike.stentzel@uni-greifswald.de. 2. Institute for Community Medicine, University Medicine Greifswald, Ellernholzstraße 1-2, 17487, Greifswald, Germany. 3. Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Ellernholzstraße 1-2, 17487, Greifswald, Germany. 4. Department of Vascular Medicine, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf (UKE), Martinistraße 52, 20246, Hamburg, Germany. 5. Bethanien Hospital for Psychiatry, Psychosomatics and Psychotherapy, Gützkower Landstraße 69, 17489, Greifswald, Germany. 6. HELIOS Hanseklinikum Stralsund, department for psychiatry and psychotherapy, Rostocker Chaussee 70, 18437, Stralsund, Germany.
Abstract
BACKGROUND: Schizophrenia and bipolar disorder are characterized by a high disease burden. Antipsychotic medication is an essential part of the treatment. However, non-adherence is a major problem. Our aim was to examine potential determinants of non-adherence for patients with severe mental disorders. METHODS: Baseline data of the study "Post stationary telemedical care of patients with severe psychiatric disorders" (Tecla) were used. Medication adherence was assessed with the Medication Adherence Report Scale German version (MARS-D). A logistic regression was calculated with age, sex, education, employment status, level of global functioning, social support and intake of typical and atypical antipsychotics as predictors. RESULTS: N = 127 participants were included in the analysis (n = 73 men, mean age 42 years). The mean MARS-D Score was 23.4 (SD 2.5). The most common reason for non-adherence was forgetting to take the medicine. Significant positive determinants for adherence were older age (OR 1.02, 95% CI 1.011-1.024, p < 0.0001), being employed (OR 2.46, 95% CI 1.893-3.206, p < 0.0001), higher level of global functioning (overall measure of how patients are doing) (OR 1.02, 95% CI 1.012-1.028, p < 0.0001), having social support (OR 1.02, 95% CI 1.013-1.026, p < 0.0001), and intake of typical antipsychotics (OR 2.389, 95% CI 1.796-3.178, p < 0.0001). A negative determinant was (female) sex (OR 0.73, 95% CI 0.625-0.859, p = 0.0001). CONCLUSIONS: Especially employment, functioning and social support could be promising targets to facilitate adherence in patients with schizophrenia or bipolar disorder. TRIAL REGISTRATION: This study is retrospectively registered at the German Clinical Trials Register with the trial registration number DRKS00008548 at 21/05/2015.
RCT Entities:
BACKGROUND:Schizophrenia and bipolar disorder are characterized by a high disease burden. Antipsychotic medication is an essential part of the treatment. However, non-adherence is a major problem. Our aim was to examine potential determinants of non-adherence for patients with severe mental disorders. METHODS: Baseline data of the study "Post stationary telemedical care of patients with severe psychiatric disorders" (Tecla) were used. Medication adherence was assessed with the Medication Adherence Report Scale German version (MARS-D). A logistic regression was calculated with age, sex, education, employment status, level of global functioning, social support and intake of typical and atypical antipsychotics as predictors. RESULTS: N = 127 participants were included in the analysis (n = 73 men, mean age 42 years). The mean MARS-D Score was 23.4 (SD 2.5). The most common reason for non-adherence was forgetting to take the medicine. Significant positive determinants for adherence were older age (OR 1.02, 95% CI 1.011-1.024, p < 0.0001), being employed (OR 2.46, 95% CI 1.893-3.206, p < 0.0001), higher level of global functioning (overall measure of how patients are doing) (OR 1.02, 95% CI 1.012-1.028, p < 0.0001), having social support (OR 1.02, 95% CI 1.013-1.026, p < 0.0001), and intake of typical antipsychotics (OR 2.389, 95% CI 1.796-3.178, p < 0.0001). A negative determinant was (female) sex (OR 0.73, 95% CI 0.625-0.859, p = 0.0001). CONCLUSIONS: Especially employment, functioning and social support could be promising targets to facilitate adherence in patients with schizophrenia or bipolar disorder. TRIAL REGISTRATION: This study is retrospectively registered at the German Clinical Trials Register with the trial registration number DRKS00008548 at 21/05/2015.
Authors: Jean-Pierre Lindenmayer; Hong Liu-Seifert; Pandurang M Kulkarni; Bruce J Kinon; Virginia Stauffer; Sara E Edwards; Lei Chen; David H Adams; Haya Ascher-Svanum; Peter F Buckley; Leslie Citrome; Jan Volavka Journal: J Clin Psychiatry Date: 2009-06-02 Impact factor: 4.384
Authors: Tanja T Menckeberg; Marcel L Bouvy; Madelon Bracke; Ad A Kaptein; Hubert G Leufkens; Jan A M Raaijmakers; Rob Horne Journal: J Psychosom Res Date: 2008-01 Impact factor: 3.006
Authors: Carl B Roth; Andreas Papassotiropoulos; Annette B Brühl; Undine E Lang; Christian G Huber Journal: Int J Environ Res Public Health Date: 2021-08-05 Impact factor: 3.390
Authors: Ulrike Stentzel; Neeltje van den Berg; Kilson Moon; Lara N Schulze; Josephine Schulte; Jens M Langosch; Wolfgang Hoffmann; Hans J Grabe Journal: BMC Psychiatry Date: 2021-06-29 Impact factor: 3.630
Authors: Philippe Courtet; Catherine Pecout; Anne-Félice Lainé-Pellet; Michael Chekroun; Charlotte Avril; Jean-Jacques Mourad Journal: JMIR Form Res Date: 2022-03-16
Authors: Heather L Wheat; Elliane Irani; Joel Hughes; Richard Josephson; Mary A Dolansky Journal: Patient Prefer Adherence Date: 2021-07-26 Impact factor: 2.711
Authors: H Sikira; S Janković; Murga S Slatina; M Muhić; S Sajun; S Priebe; A Džubur Kulenović Journal: Epidemiol Psychiatr Sci Date: 2021-06-11 Impact factor: 6.892